Research
Hormonal
GLP-1 receptor agonists increase perioperative aspiration risk due to delayed gastric emptying, requiring specific holding protocols before elective surgery.
If you are having elective surgery while taking GLP-1 medications, tell your surgeon and anesthesiologist. You may need to hold your medication before surgery to reduce the risk of aspiration. Follow the specific holding instructions provided by your medical team.
GoodSupportsHIGH confidence
The most commonly reported side effects of GLP-1 receptor agonists are gastrointestinal in nature... delayed gastric emptying may raise the risk of vomiting and aspiration during intubation.
Why this rating
Based on ASA guidelines and retrospective cohort studies.
Source
“Ozempic Face” in Plastic Surgery: A Systematic Review of the Literature on GLP-1 Receptor Agonist Mediated Weight Loss and Analysis of Public Perceptions
Giulia Daneshgaran et al. · Aesthetic Surgery Journal Open Forum · 2025
DOI 10.1093/asjof/ojaf056
systematic_reviewCited 8×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP-1 receptor agonist-mediated weight loss causes facial volume loss and skin laxity that mimics advanced aging, a phenomenon termed 'Ozempic face,' which is managed through volume restoration (fillers/fat grafting) or skin tightening procedures.Good
- Discontinuation of GLP-1 receptor agonists leads to significant weight regain (up to two-thirds of lost weight) and reversal of cardiometabolic improvements.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →